Inventor · disambiguated record
Walter Mier
Also filed as: MIER WALTER
22 granted patents·19 pending applications·151 citations·filing 1997–2024
94Inventor score
Files withDEUTSCHES KREBSFORSCH11UNIV HEIDELBERG9UNIV HEIDELBERG RUPRECHT KARLS5MIER WALTER4MERCK PATENT GMBH3
Top patents by PatentIndex Score
41 records- 0196US11951190B2Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2021·Granted Apr 9, 2024·4 cites·62 claims
- 0296US11931430B2Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2020·Granted Mar 19, 2024·5 cites·15 claims
- 0396US11045564B2Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Granted Jun 29, 2021·10 cites·15 claims
- 0496US10398791B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Sep 3, 2019·22 cites·30 claims
- 0594US10471160B2Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2018·Granted Nov 12, 2019·16 cites·28 claims
- 0690US2024382631A1Use of labeled inhibitors of prostate specific membrane antigen (psma), as agents for the treatment of prostate cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0789US2024350680A1Labeled inhibitors of prostate specific membrane antigen (psma) as agents for the treatment of prostate cancerNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0887US9078929B2ε-Polylysine conjugates and the use thereofKUEBELBECK ARMIN·Filed 2010·Granted Jul 14, 2015·16 cites·17 claims
- 0983US10065993B2Peptides and peptide/active compound conjugates for renal targetingMERCK PATENT GMBH·Filed 2014·Granted Sep 4, 2018·7 cites·20 claims
- 1083US9562076B2Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as HBV and HDV entry inhibitorsMIER WALTER·Filed 2009·Granted Feb 7, 2017·8 cites·41 claims
- 1179US2025127937A1Fap inhibitorUNIV HEIDELBERG·Filed 2024·Application pending·0 cites
- 1276US11401304B2Cyclic NTCP-targeting peptides and their uses as entry inhibitorsUNIV HEIDELBERG RUPRECHT KARLS·Filed 2016·Granted Aug 2, 2022·1 cites·8 claims
- 1374US10253099B2Conjugates of proteins and multivalent cell-penetrating peptides and their usesUNIV HEIDELBERG RUPRECHT KARLS·Filed 2013·Granted Apr 9, 2019·3 cites·20 claims
- 1474US2025057993A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancersUNIV HEIDELBERG·Filed 2024·Application pending·0 cites
- 1571US2019336622A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2019·Application pending·0 cites
- 1671US2023112012A1Fap inhibitorUNIV HEIDELBERG·Filed 2022·Application pending·0 cites
- 1770US9808535B2Conjugates for protection from nephrotoxic active substancesMERCK PATENT GMBH·Filed 2014·Granted Nov 7, 2017·1 cites·7 claims
- 1869US9868768B2Hydrophobic modified pres-derived peptides of hepatitis B virus (HBV) and their use as vehicles for the specific delivery of compounds to the liverMIER WALTER·Filed 2009·Granted Jan 16, 2018·1 cites·20 claims
- 1966US6891033B2Labelling compounds for the simple synthesis of 3'-[18F]fluoro-3'-deoxythymidine and a method for the production thereofDEUTSCHES KREBSFORSCH·Filed 2002·Granted May 10, 2005·5 cites·11 claims
- 2065US2021038749A1Fap inhibitorUNIV HEIDELBERG·Filed 2019·Application pending·0 cites
- 2162US2016228587A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancerDEUTSCHES KREBSFORSCH·Filed 2016·Application pending·0 cites
- 2261US6369109B1Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumorDEUTSCHES KREBSFORSCH·Filed 1998·Granted Apr 9, 2002·33 cites·18 claims
- 2361US2021393809A1Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancersUNIV HEIDELBERT·Filed 2019·Application pending·0 cites
- 2459US6417339B1Dendrimers based on saccharidesDEUTSCHES KREBSFORSCH·Filed 1997·Granted Jul 9, 2002·19 cites·19 claims
- 2556US2025206780A1Cyclic peptides and their use for the treatment of diseases associated with dicarbonyls like methylglyoxalUNIV HEIDELBERG·Filed 2023·Application pending·0 cites
- 2653US10413614B2Conjugates for protection from nephrotoxic active substancesMERCK PATENT GMBH·Filed 2017·Granted Sep 17, 2019·0 cites·8 claims
- 2753US2023211003A1Conjugate compounds for preventing and/or treating hbv and/or hdv infections, liver diseases andfor targeting ntcpUNIV HEIDELBERG·Filed 2020·Application pending·0 cites
- 2852US2020283503A1Cd44v6-derived cyclic peptides for treating cancers and angiogenesis related diseasesAMCURE GMBH·Filed 2020·Application pending·0 cites
- 2949US10703796B2CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseasesAMCURE GMBH·Filed 2015·Granted Jul 7, 2020·0 cites·19 claims
- 3049US2007202047A1Polyamine-substituted ligands for use as contrast agentsWOLF MARKUS·Filed 2007·Application pending·0 cites
- 3148US2022324898A1Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linkerDEUTSCHES KREBSFORSCH·Filed 2020·Application pending·0 cites
- 3242US2020131227A1Polypeptide with tumour binding activityUNIV HEIDELBERG RUPRECHT KARLS·Filed 2018·Application pending·0 cites
- 3342US2001029035A1Oligonucleotide conjugatesFiled 2001·Application pending·0 cites
- 3440US10653796B2Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromoleculesUNIV HEIDELBERG·Filed 2016·Granted May 19, 2020·0 cites·13 claims
- 3540US10363323B2Hydrophobic modified peptides for liver specific diagnosisMIER WALTER·Filed 2012·Granted Jul 30, 2019·0 cites·40 claims
- 3639US11202833B2Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levelsUNIV HEIDELBERG RUPRECHT KARLS·Filed 2017·Granted Dec 21, 2021·0 cites·9 claims
- 3739US10716757B2Liposomal formulation for the oral hepatic delivery of drugsUNIV HEIDELBERG·Filed 2016·Granted Jul 21, 2020·0 cites·2 claims
- 3839US2020022914A1Liposomal compositions and solid oral dosage forms comprising the sameUNIV HEIDELBERG·Filed 2018·Application pending·0 cites
- 3939US2019351069A1Coating of Nanoparticle Surfaces with Cyclopeptides for Improving Delivery of Agents Via the Oral RouteUNIV HEIDELBERG RUPRECHT KARLS·Filed 2017·Application pending·0 cites
- 4036US10513539B2Hydrophobic modified peptides and their use for liver specific targetingMIER WALTER·Filed 2012·Granted Dec 24, 2019·0 cites·38 claims
- 4124US2003119051A1Saccharide libraryFiled 1997·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Walter Mier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →